Signaling networks assembled by oncogenic EGFR and c-Met. - Test2 - elhamkhani - TriplyDB

Signaling networks assembled by oncogenic EGFR and c-Met.

Signaling networks assembled by oncogenic EGFR and c-Met.

http://www.wikidata.org/entity/Q36392991

about

Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactome A secreted tyrosine kinase acts in the extracellular environment Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at arrested endocytic clathrin-coated pits of cells that lack dynamin Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling EGFR/Met association regulates EGFR TKI resistance in breast cancer An overview of the c-MET signaling pathway The impact of microRNAs on protein output Selective Sensing of Tyrosine Phosphorylation in Peptides Using Terbium(III) Complexes Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer Analysis of oncogenic signaling induced by tyrosine kinases in tumors by SILAC-based quantitative proteomic approach Post-translational modifications of intermediate filament proteins: mechanisms and functions Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts Assessment, origin, and implementation of breath volatile cancer markers.Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review Biology of MET: a double life between normal tissue repair and tumor progression Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Systems Proteomics View of the Endogenous Human Claudin Protein Family Sticky signaling--adhesion class G protein-coupled receptors take the stage Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells Receptor tyrosine kinase (RTK) mediated tyrosine phosphor-proteome from Drosophila S2 (ErbB1) cells reveals novel signaling networks Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification SH3 interactome conserves general function over specific form.Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Src-dependent tyrosine phosphorylation of non-muscle myosin heavy chain-IIA restricts Listeria monocytogenes cellular infection The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.Reconstructing targetable pathways in lung cancer by integrating diverse omics data Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.Mass spectrometry identifies multiple organophosphorylated sites on tubulin.Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation.In-depth qualitative and quantitative profiling of tyrosine phosphorylation using a combination of phosphopeptide immunoaffinity purification and stable isotope dimethyl labeling Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.Novel Ser/Thr protein phosphatase 5 (PP5) regulated targets during DNA damage identified by proteomics analysis.

P2860

Q24294625-B540A7EE-EF51-4C58-9E8F-C2905BE86872 Q24303065-D8E02F85-A2BA-450E-A6AB-5FCA6019B0A5 Q24317755-E1F7EE4A-C39D-431C-A13B-F77EC4CCC3E4 Q24319111-AA528B8F-F728-4B62-9610-623AA55CB592 Q24338635-F4ED1BAC-1DF5-4C4A-87CB-0F9E37B81316 Q24633986-6DFD1A64-A01F-4E2D-B82C-00F6764198EA Q24653549-2D8DC8D4-30E1-46D7-BBBB-A95025AA65A6 Q26744839-5010E95B-8894-4D0D-BC1C-C191B06621FD Q26852215-51C5F372-5AC7-4EB4-B57A-5D8B57B1F0A3 Q26852884-F820BDC5-2823-4B41-9F76-3F12CA1AC421 Q27004670-0D185D18-FC19-42DD-8D22-6E887CD5FB6F Q27027957-C6E19FE6-7F67-45A0-9A7B-962D49A232AE Q27317429-5DAE1DD9-2160-4F55-A18E-2F9B7AF37FC7 Q27319837-68594A14-6941-45CE-B785-0F339A3D26F0 Q27692565-1E81FDAB-18C0-467B-A27F-11DBC8959DE2 Q28074119-38C0EA00-F0ED-4DB7-A4CE-CEA981893C4D Q28085247-28361EAC-CAD7-4197-BC59-C8C9A24CAC38 Q28115584-CD7A8244-984B-44BA-A355-080764991E1C Q28240702-D2A73C62-6C4D-4B45-A25E-9A4180932AE4 Q28271194-B93FE7B2-4AC4-4C98-BB7C-6FF627A9D58F Q28291130-F5DD8E10-47C9-4187-9935-A9D3AEE4C7BA Q28468579-1BF98906-0C8D-4EB0-B535-32EFCF3FEE93 Q28473351-D80587BB-A058-4D27-A52A-F7E2D6E644E5 Q28484238-2567C8A5-5C75-4FC5-A79E-FCFD2DA919F2 Q28534577-B97FC5C5-1FAC-4107-AC8D-27B0AC144BF2 Q30009888-FBFA346B-A081-44AF-BB39-01DCA6199A6B Q30278774-8F0AA130-418B-406D-B411-AFBD214CF0AB Q30360087-8C2FFD96-6C6C-4636-8456-F81ECB4665C8 Q30494514-2C98E537-795F-4AAD-A0D6-DB3ACBD1C378 Q30537354-BCB6966D-2EC2-4C5A-81A1-B3A6D00424AA Q30679547-5D4D807B-6112-45D4-BA8F-6336CBE79D55 Q30931456-F589C43C-533B-493B-AF74-EE518814D71A Q31062741-350B25B2-970B-4069-BCE4-6893CDD6AABA Q33411775-E3439DC3-D1D3-418F-BF39-2200DB5E86D2 Q33486958-4755D72E-F6FF-4417-B126-E937E25D61E1 Q33487694-E09549C8-9C4F-47F7-81A1-4E6DD240C059 Q33598027-CFCA051B-0D74-4B35-91B2-7756708AACA4 Q33602552-EED34AB1-1FDE-4521-8B95-DB145A960874 Q33614314-D482ABEB-981D-4009-8426-C8D17B135242 Q33639959-8256D0D8-F7B4-4C02-98DD-8A4A59D67813

P2860

Signaling networks assembled by oncogenic EGFR and c-Met.

http://www.wikidata.org/entity/Q36392991

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Signaling networks assembled by oncogenic EGFR and c-Met.

@ast

Signaling networks assembled by oncogenic EGFR and c-Met.

@en

type

label

Signaling networks assembled by oncogenic EGFR and c-Met.

@ast

Signaling networks assembled by oncogenic EGFR and c-Met.

@en

prefLabel

Signaling networks assembled by oncogenic EGFR and c-Met.

@ast

Signaling networks assembled by oncogenic EGFR and c-Met.

@en

P1433

Q36392991-B2F5B9A7-B254-4CCE-AC19-3FCE12534423

P1476

Q36392991-CC2E3020-9E16-43E9-A5B3-58466ADB4BB5

P2093

Q36392991-0CCDFC5D-AA82-4B22-AE69-A287D466D6C1

Q36392991-1836E623-0F0F-405E-9BC3-66C043928E27

Q36392991-193AADBD-B0B3-403A-B4CE-EF539DBC3E8F

Q36392991-2FB858C9-6F34-4724-9504-7298F7DD08D4

Q36392991-384B1134-828C-45C6-917B-28293DE4B0F7

Q36392991-3E3426F6-A66E-4608-8B85-BDC7300533C5

Q36392991-413B0048-61F3-4885-8F66-CD21FCB8864E

Q36392991-51103DB2-1797-4E9B-8BBA-62DC68ED1C81

Q36392991-63E6924D-F946-4E13-AD95-32042F415A79

Q36392991-76CEABC2-8CD5-42C5-BFB9-4EC63726F213

P2860

Q36392991-0453A7E2-6789-4B00-85A2-754DF4B2F2BF

Q36392991-11998E64-092A-4420-8B3A-97DBBDCB622F

Q36392991-13839C4F-A712-4628-BEB4-A2D83814A65B

Q36392991-2301CD05-7F43-45A6-B9A7-2564A3F45631

Q36392991-4C2C47F8-93D6-43AC-89C7-842A1686A433

Q36392991-51E8FB6B-24DB-4C98-B01E-BCE01BE73E5A

Q36392991-544DD096-0CEE-4EA5-83FB-F8ADB490F0B9

Q36392991-598450B9-6A41-4C75-B1CC-472F702F3730

Q36392991-62D45426-3266-40F4-885E-1D9BB04B1254

Q36392991-63A0A178-9C79-4786-8685-7C5C16C4DB51

P304

Q36392991-2A437D0E-81A7-4058-87DD-6AF40F99271C

P31

Q36392991-F75923A9-53C3-4A78-9374-239C8920969E

P356

Q36392991-9E3E0D13-E771-4020-B8E3-D32078519DE8

P407

Q36392991-C32D3221-0D3A-452F-987B-578747E8A34E

P433

Q36392991-BBE70CDC-B86B-49C1-800A-EE53F0F4BE61

P478

Q36392991-B40B86D6-F213-43BD-A6D6-3C934AFF989F

P50

Q36392991-0D94B76A-608D-452B-B100-82E523C5942B

Q36392991-3E909773-4CB6-442C-A462-E04AC343973E

P577

Q36392991-FEFA03BE-B3EB-4952-9A7A-BDA2FCB13F5D

P5875

Q36392991-671C22D4-7D10-4907-A2FF-2A1DDB3BE51A

P698

Q36392991-C62F3706-BFE3-4F9A-9852-E1579A66DA40

P932

Q36392991-324A42B9-E5DA-4FC1-98B4-A20F2FFDED0E

P356

PNAS.0707270105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Signaling networks assembled by oncogenic EGFR and c-Met.

@en

P2093

Ailan Guo

http://www.w3.org/2001/XMLSchema#string

Anthony Possemato

http://www.w3.org/2001/XMLSchema#string

Gregory Innocenti

http://www.w3.org/2001/XMLSchema#string

Jeffrey Mitchell

http://www.w3.org/2001/XMLSchema#string

Joan MacNeill

http://www.w3.org/2001/XMLSchema#string

John Rush

http://www.w3.org/2001/XMLSchema#string

Jon Kornhauser

http://www.w3.org/2001/XMLSchema#string

Julie Nardone

http://www.w3.org/2001/XMLSchema#string

Kimberly A Lee

http://www.w3.org/2001/XMLSchema#string

Klarisa Rikova

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Immunoaffinity profiling of tyrosine phosphorylation in cancer cells

Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

P304

692-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0707270105

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5670811

http://www.w3.org/2001/XMLSchema#string

P698

18180459

http://www.w3.org/2001/XMLSchema#string

P932

2206598

http://www.w3.org/2001/XMLSchema#string